Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$19.68
$11.48
$19.75
$384.69M1.35129,776 shs8,375 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$2.24
-3.0%
$2.55
$1.64
$12.51
$748.01M0.868.92 million shs8.78 million shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$29.00
-2.0%
$26.94
$16.28
$38.93
$816.23M0.42190,874 shs156,488 shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.94
-2.9%
$6.71
$5.01
$17.81
$1.12B2.816.53 million shs5.16 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00%0.00%0.00%0.00%0.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+9.27%+27.27%-37.60%-73.74%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
0.00%-9.26%+6.07%+13.95%+55.00%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-6.85%+10.33%-13.14%-56.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.6367 of 5 stars
4.31.00.04.22.24.21.3
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
1.4995 of 5 stars
3.61.00.00.02.20.80.0
Novavax, Inc. stock logo
NVAX
Novavax
3.8533 of 5 stars
3.32.00.04.72.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00
N/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.50
Moderate Buy$13.30493.75% Upside
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
3.17
Buy$46.6060.69% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.50
Moderate Buy$19.20176.66% Upside

Current Analyst Ratings Breakdown

Latest CBMG, NVAX, IOVA, and LENZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $25.00
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $20.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$340K0.00N/AN/A$2.89 per share0.00
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$212.68M3.52N/AN/A$2.28 per share0.98
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$22.06 per shareN/A
Novavax, Inc. stock logo
NVAX
Novavax
$1.21B0.93N/AN/A($6.04) per share-1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$444.04M-$1.24N/AN/AN/A-451.25%-58.43%-45.48%8/6/2025 (Estimated)
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M$2.65N/A86.752.85-32.18%N/A-17.05%8/14/2025 (Estimated)

Latest CBMG, NVAX, IOVA, and LENZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/7/2025Q1 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.55-$0.53+$0.02-$0.53N/AN/A
3/19/2025Q4 2024
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/A
0.47
0.47
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.22
3.90
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
28.63
28.63
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93

Institutional Ownership

CompanyInstitutional Ownership
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21.98%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
8.50%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
10.30%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
6.90%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21719.48 millionN/AOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million267.90 millionOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.15 million16.94 millionN/A
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million158.58 millionOptionable

Recent News About These Companies

Novavax: New Vaccine, Same Old Story - Still A Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellular Biomedicine Group stock logo

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$2.24 -0.07 (-3.03%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.24 -0.01 (-0.22%)
As of 06/13/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$29.00 -0.58 (-1.96%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$29.08 +0.08 (+0.28%)
As of 06/13/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.94 -0.21 (-2.94%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$7.02 +0.07 (+1.08%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.